SHaRe Registry Identifies MACE Predictors in Mild HCM
A study of 2,500 patients in the SHaRe Registry found that one in five individuals with mild hypertrophic cardiomyopathy experienced major adverse cardiovascular events over seven years. Key risk predictors included older age, symptom progression, and specific structural heart measurements.
Why it matters
Identifying these predictors helps clinicians better manage patients previously considered low-risk, potentially preventing serious outcomes like heart failure or sudden cardiac death.
About one in five patients with phenotypically mild hypertrophic cardiomyopathy (HCM) experienced major adverse cardiovascular events (MACE) over seven years of follow-up, according to SHaRe Registry research published July 8 in JACC . Older age, symptom progression and increases in left atrial (LA) diameter, left ventricular (LV) hypertrophy and LV outflow tract (LVOT) gradient were among the strongest predictors of risk.
The article reports on clinical research findings from a medical registry without political or social framing.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in